News|Articles|October 4, 2024
Quality by Design (QbD) for Biologics: A CDMO's Perspective
Author(s)Catalent
By integrating QbD into the development process, organizations can achieve robust manufacturing processes, regulatory compliance, and commercial success.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
BioPharm Weekly News Roundup—Week of Oct. 13, 2025
3
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
